Titan Pharmaceuticals Inc TTNP Fundamentals and Key Ratios

Titan Pharmaceuticals Inc. (TTNP) Fundamentals


Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

SHARE INFORMATION
Market Cap	$ 10,922,173
Shares Outstanding	14,629,217
Float	14,571,587
Percent Float	99.61%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 1,526,000
Latest Fiscal EPS	$ -0.90
Latest Fiscal Date	2021-12-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	35
Institutional Holdings Date	2023-02-28
Institutional Bought Previous 3 Months	163
Institutional Holdings Percent	8.0%
Institutional Sold Previous 3 Months	162,096
Insider Holdings Date	2023-02-28
Insider Bought Previous 3 Months	57,500
Insider Holdings Percent	18.4
Insider Sold Previous 3 Months	-
Insider Shares Owned	2,694,554

TRADING INFO
52 Week High	$ 1.59
52 Week Low	$ 0.35
52 Week High Change	$ -26.80
21 Day Moving Average	$ 0.844
21 Day Extended Moving Average	$ 0.827122
50 Day Moving Average	$ 0.9109
50 Day Extended Moving Average	$ 0.879075
200 Day Moving Average	$ 1.0161
200 Day Extended Moving Average	$ 1.0127
10 Day Average Volume	23,286
20 Day Average Volume	18,762
30 Day Average Volume	17,739
50 Day Average Volume	28,615
Alpha	-0.051434
Beta	1.0935
Standard Deviation	0.293361
R2	0.040290
7 Day Price Change	$ -0.0334
7 Day Percent Change	-4.28%
21 Day Price Change	$ -0.1934
21 Day Percent Change	-20.57%
30 Day Price Change	$ -0.1645
30 Day Percent Change	-18.06%
Month to Date Price Change	$ -0.1858
Month to Date Percent Change	-19.93%
Quarter to Date Price Change	$ -0.0365
Quarter to Date Percent Change	-4.66%
180 Day Price Change	$ -0.3134
180 Day Percent Change	-29.57%
200 Day Price Change	$ -0.5834
200 Day Percent Change	-43.86%
Year to Date Price Change	$ -0.0365
Year to Date Percent Change	-4.66%

PROFITABILITY
EBIT Margin	-784.0%
EBITDA Margin	-768.1%
Pre-Tax Profit Margin	-871.2%
Profit Margin Count	-38.2%
Gross Margin	100.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 9,000
Revenue Per Share	$ 0.0006
Revenue (3 Years)	$ -77.54
Revenue (5 Years)	$ -26.08

FINANCIAL STRENGTH
Price to Tangible Book	3.10
Total Debt To Equity	0.10
Int Coverage	-9,048.90
Current Ratio	2.20
Leverage Ratio	1.50
Quick Ratio	1.70
Long Term Debt To Capital	0.03

VALUATION MEASURES
PE Ratio	14.60
Enterprise Value	$ 6,688,173
Price to Sales	1,213.5747
Price to Free Cash	-1.70
PE High Last 5 Years	25.30
Price To Book	3.10
Price To Cash Flow	7.90
PE Low Last 5 Years	-0.20
Price to Tangible Book	3.10

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.10
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-141.00
Return on Equity	-205.65
Return on Capital	-175.71

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	OUM & Co. LLP
CEO	David E. Lazar
Emplyoees	11
Last Audit	UE
CIK	0000910267
Industry	Biotechnology
Sector	Healthcare
NAICS	Biological Product (except Diagnostic) Manufacturing(325414)

CONTACT INFO
Address	400 Oyster Point Boulevard Suite 505 South San Francisco, CA 94080
Website	https://www.titanpharm.com
Facsimile	+1 650 244-4956
Telephone	+1 650 244-4990
Email	-

Boards:

Quotes:

TTNP